Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents (2023 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Zhengye Biotechnology Holding (ZYBT) has disclosed Cash & Equivalents for 2 consecutive years, with $2.6 million as the latest value for Q4 2024.

• Quarterly Cash & Equivalents rose 23.72% to $2.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2024, up 23.72% year-over-year, with the annual reading at $2.5 million for FY2024, 19.51% up from the prior year.
• Cash & Equivalents for Q4 2024 was $2.6 million at Zhengye Biotechnology Holding, up from $2.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $2.6 million in Q4 2024, with the low at $2.1 million in Q4 2023.

Peer Comparison